Processa Pharmaceuticals is a biopharmaceutical company focused on utilizing the Processa Regulatory Science Approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. Co.'s pipeline consists of three oncology drugs: NGC Capecitabine, which is an orally administered irreversible inhibitor of the enzyme dihydropyrimidine dehydrogenase; NGC-Gemcitabine, which is a cytidine analog similar to gemcitabine (Gemzar®), but different enough in chemical structure that some patients are more likely to respond to PCS3117 than gemcitabine; and NGC-Irinotecan, which is an analog of SN38, the active metabolite of irinotecan; and two non-oncology drugs: PCS12852 and PCS499. The PCSA YTD return is shown above.
The YTD Return on the PCSA YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether PCSA YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the PCSA YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|